Inhibition of complement action

• US 7,049,282 B2
• Filed: 10/26/2001
• Issued: 05/23/2006
• Est. Priority Date: 04/26/1999
• Status: Expired due to Fees

• Current Assignee: Duke University
• Original Assignee: Duke University
• Inventors: Frank, Michael M., Jiang, Haixiang J.
• Primary Examiner(s): Kerr, Kathleen M.
• Assistant Examiner(s): ROBINSON, HOPE A
• Application Number:
  US09/984,017
• Publication Number:
  US 20020115614A1
• Time in Patent Office: 1,670 Days
• Field of Search: 514/2, 514/21, 514/14, 514/15
• US Class Current: 514/15.2
• CPC Class Codes: A61K 2039/505 comprising antibodies
• CPC Class Codes: C07K 16/00 Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies antibodies with enzymatic activity, e.g. abzymes C12N9/0002
• CPC Class Codes: C07K 2317/52 Constant or Fc region; Isotype

Abstract

The present invention relates to a method of blocking biochemical function of the classical complement pathway and thereby preventing immunologic damage in a variety of diseases and conditions including autoimmune diseases.

Claims

1. A method of blocking a complement pathway in a patient in need thereof comprising administering to said patient a complement pathway blocking amount of the peptide WESNGQPENN (SEQ ID NO:

1) or KTISKAKGQPREPQVYT (SEQ ID NO;

2), so that said blocking is effected.

2. The method according to claim 1 wherein said patient suffers from an autoimmune disease.

3. The method according to claim 1 wherein blocking of said complement pathway reduces immunologic tissue damage in said patient, in comparison to immunologic tissue damage that results if said peptide is not administered.

4. The method according to claim 1 wherein said patient is a recipient of a xenograft and blocking of said complement pathway reduces hyperacute rejection of said xenograft, in comparison to hyperacute rejection that result if said peptide is not administered.

5. A peptide consisting of the sequence WESNGQPENN (SEQ ID NO:

1).

7. A composition comprising the peptide according to claim 5 and a pharmaceutically acceptable carrier.

6. A peptide consisting of the sequence KTISKAKGQPREPQVYT (SEQ ID NO:

2).

8. A composition comprising the peptide according to claim 6 and a pharmaceutically acceptable carrier.

9. A method of blocking a complement pathway in a patient in need thereof comprising administering to said patient a complement blocking amount of a peptide consisting the sequence of SEQ ID NO:

1 or SEQ ID NO;

2, further comprising a radiolabeled C or N terminal cysteine, so that said blocking is effected.

10. The method according to claim 9, wherein the peptide of SEQ ID NO:

1, further comprising a radiolabeled C or N terminal cysteine, is administered.

11. A composition comprising the peptide of SEQ ID NO:

1 or the peptide SEQ ID NO;

2, wherein said peptide is coupled to a protein.

12. The composition according to claim 11 wherein said protein is serum albumin.

13. The composition according to claim 11 wherein said peptide is coupled to said protein with glutaraldehyde.